Deep Brain Stimulation Devices Market Size, Share & Trends Report

Deep Brain Stimulation Devices Market Size, Share & Trends Analysis Report By Product (Single Channel, Dual-channel), By Application, By End-use, By Region, And Segment Forecasts, 2021 - 2028

  • Published Date: Feb, 2021
  • Base Year for Estimate: 2020
  • Report ID: 978-1-68038-335-5
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019
  • Number of Pages: 164

Report Overview

The global deep brain stimulation devices market size was valued at USD 1.12 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 9.3% from 2021 to 2028. Increasing number of patients suffering from involuntary movements associated with Parkinson’s disease, dystonia, and multiple sclerosis is expected to drive market growth. In addition, increasing demand for minimally invasive techniques due to enhanced patient outcomes is also a high-impact rendering driver for the market for deep brain stimulation (DBS) devices.

U.S. deep brain stimulation devices market size, by product, 2016 - 2028 (USD Million)

Deep brain stimulation is the surgery for implanting a device that sends a signal to brain areas responsible for body movement. DBS helps in reducing the symptoms of stiffness, slowness, and walking problems caused by various neurological diseases such as dystonia, Parkinson’s disease, or essential tremor. This therapy is generally recommended to patients who do not respond to medicines for at least five years. Moreover, this treatment is approved by the U.S. FDA for patients who cannot have epilepsy surgery, which separates or removes the part of the brain that causes seizures. Thus, the rising prevalence of neurological conditions, such as Alzheimer’s and Parkinson’s disease is the major factor driving the growth of the market.

Increasing prevalence of neurological disorders, such as Parkinson’s disease, essential tremors, dystonia, and epilepsy, is a high-impact rendering driver for the deep brain stimulators market. According to WHO, neurological diseases contribute 6.3% to the global disease burden and are one of the major causes of mortality worldwide, resulting in 13.2% deaths in developed countries and 16.8% in low- and middle-income countries. High mortality and disease burden create clinical urgency for the incorporation of long-term solutions such as deep brain stimulators. Furthermore, growing awareness about the massive neurological disease burden has raised the demand for deep brain stimulators as an alternative therapy. This is expected to drive market growth during the forecast period.

Furthermore, technological advancements in deep brain stimulation technologies are anticipated to create growth opportunities in this market. These technological improvements include robot-assisted implantation, improved microelectrode designs, multi-target stimulation, rechargeable implantable pulse generators, and personalized directed programming. Owing to these advancements, DBS devices are showing fewer adverse effects and improved efficacy and symptomatic relief in patients suffering from Parkinson’s, as compared to the traditional methods. For instance, Abbott's Infinity Deep Brain Stimulation (DBS) System is a technologically enhanced new DBS that can help patients with their symptoms. It is the first wireless iOS software DBS mobile platform that offers efficient and personalized therapy management with reduced risk of adverse effects.

Countries such as U.S. and Canada have witnessed a high prevalence rate of movement and psychiatric disorders coupled with an increasing geriatric population. For instance, according to Parkinson's Foundation, symptoms of PD are common at an average age of 60. The geriatric population is highly susceptible to these disorders. Similarly, according to Canadian Psychological Association, around 2.0% of the population is suffering from obsessive compulsive disorder. Moreover, an increase in FDA approvals for deep brain stimulation devices in clinical applications, such as tremors, severe obsessive compulsive disorders, and dystonia, is fueling the market. For instance, in March 2020, NeuroPace, Inc. received approval from the U.S. FDA of MRI labeling for its RNS System. These factors are expected to boost the demand for DBS devices in these countries.

Furthermore, severe adverse effects and drug interactions owing to drug absorption by non-targeted sites are anticipated to boost the need for a targeted therapy approach, propelling the demand for DBS devices. These drugs can offer significant improvements in motor function; however, they may lead to adverse effects, particularly when the disease progresses. For instance, constant administration of the drug levodopa may result in long-term complications such as hallucinations, dyskinesia, neurotoxic effects, and severe metabolic changes. Thus, adverse effects such as these drive the clinical need to incorporate alternatives based on targeted therapy approaches, including deep brain stimulators. This, in turn, is boosting the market growth during the forecast period.

Product Insights

The dual-channel segment dominated the market for deep brain stimulation devices and accounted for a revenue share of 57.2% in 2020 owing to its higher adoption in surgical procedures. Dual channel are one of the safest and most effective devices used in surgical procedures. Thus, the high prevalence of disabling neurological diseases, an increasing number of surgical procedures for PD, and the growing number of hospitals using dual-channel DBS devices are driving the segment.

However, the single-channel deep brain stimulation device segment is expected to witness the highest CAGR of 9.5% from 2021 to 2028. Healthcare professionals believe that single-channel offers more programming options to neurologists, which led to increased preference for single-channel DBS devices. According to the Parkinson’s Foundation, the geriatric population is more prone to neurological diseases. Thus, the increasing geriatric population, growing awareness about neurological diseases among patients, and preference by healthcare professionals are anticipated to trigger the segment growth.

Application Insights

The Parkinson's disease segment dominated the market for deep brain stimulation devices and accounted for a revenue share of 65.2% in 2020 owing to the increasing number of U.S. FDA approvals for deep brain stimulation therapies and the high prevalence of PD worldwide. In December 2017, Boston Scientific Corporation received approval for the Vercise deep brain stimulation device system from the U.S. FDA for the treatment of PD. According to the Parkinson’s Foundation, around 60,000 people in the U.S. are diagnosed with PD every year. This is expected to drive the segment growth in the coming years.

However, the epilepsy segment is expected to witness the highest CAGR of 16.2% from 2021 to 2028. Growing awareness about advanced treatment options for epilepsy coupled with developing healthcare infrastructure is expected to further fuel segment growth in the coming years. According to the WHO, approximately 50 million people are suffering from epilepsy and it is one of the most common neurological diseases worldwide. deep brain stimulation is used in epilepsy due to the low therapeutic response of medication in seizures and reduced success rates associated with surgeries. This, in turn, will further lead to segment growth.

End-use Insights

In the end-use segment, hospitals dominated the market for deep brain stimulation devices and accounted for the largest revenue share of 52.0% in 2020. The growth of this segment can mainly be attributed to the increase in number of DBS surgeries performed in hospitals and the surge in prevalence of Parkinson’s disease, essential tremor. Furthermore, the availability of technologically advanced DBS devices coupled with favorable reimbursement policies is expected to drive the segment during the forecast period. For instance, Medtronic offers comprehensive services to secure and maintain coverage as well as payment for various DBS devices.

France deep brain stimulation devices market share, by end use, 2020 (%)

However, Ambulatory Surgical Centers (ASC) segment is expected to grow at the highest CAGR of 9.8% from 2021 to 2028. This is due to the lower cost of procedures as compared to hospitals, convenient access for patient care, reduced waiting time, and low infection rate as compared to neurology clinics and hospitals. Furthermore, according to a study conducted by Advancing Surgical Care, 92% of patients were satisfied with the medical care and service provided in the ASCs, thus, boosting segment growth

Regional Insights

North America dominated the Deep Brain Stimulation devices market with a share of 51.9% in 2020 owing to an increase in FDA approvals for deep brain stimulation devices in clinical applications. For instance, in 2015, the U.S. FDA approved a deep brain stimulation device, Brio, for the treatment of Parkinson’s disease. Furthermore, an increasing number of patients diagnosed with PD coupled with rising government funding and initiatives for raising awareness about movement disorders is expected to drive the demand for deep brain stimulation devices in the region.

However, Asia Pacific is expected to significantly lead the market for deep brain stimulation devices in the future from 2021 to 2028. This is attributed to the rising prevalence of neurodegenerative disorders coupled with unmet demand for effective and long-term solutions. Rising awareness about neurological disease treatment options and improvements in the clinical development framework of emerging economies is expected to drive the market for deep brain stimulation devices in this region. Moreover, the presence of high growth opportunities in developing countries such as Japan, China, and India are likely to contribute to market growth.

Key Companies & Market Share Insights

The key players are increasingly focusing on product launches, technological advancements, and other growth strategies, such as mergers and acquisitions to strengthen their foothold in the market. For instance, in September 2019, LivaNova together with MicroPort Scientific received the approval of RegaTM pacemakers from the FDA China. These are the smallest pacemakers in the cardiac rhythm management market in China. This approval will strengthen the company’s local presence and expand its footprint in China.

Emerging players such as NeuroPace, Inc., and Aleva Neurotherapeutics SA, are considered innovators in the market for deep brain stimulation devices. Products offered by these competitors have good price-performance propositions, competitive functionality, and are technologically advanced. These players are focusing on product commercialization activities as well as fundraising activities to support the R&D growth. For instance, in October 2017, NeuroPace, Inc. closed a USD 74 million funding round initiated by OrbiMed Advisors and KCK Groups. The funding will support the company’s ongoing efforts for rapid expansion and commercialization of its FDA-approved DBS product- NeuroPace RNS system. Some of the prominent players in the deep brain stimulation devices market include:

  • Abbott (St. Jude Medical)

  • Medtronic

  • Boston Scientific Corporation

  • Aleva Neurotherapeutics S.A.

  • Nexstim

  • LivaNova PLC

  • Neuropace Inc.

Deep Brain Stimulation Devices Market Report Scope

Report Attribute

Details

Market size value in 2021

USD 1.22 billion

Revenue forecast in 2028

USD 2.3 billion

Growth Rate

CAGR of 9.3% from 2021 to 2028

Base year for estimation

2020

Historical data

2016 - 2019

Forecast period

2021 - 2028

Quantitative units

Revenue in USD million and CAGR from 2021 to 2028

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; Netherlands; Switzerland; Sweden; Ireland; Poland; Japan; China; India; Australia; South Korea; Indonesia; Thailand; Philippines; Malaysia; Singapore; Brazil; Mexico; Colombia; Argentina; Chile; Venezuela; South Africa; Saudi Arabia; UAE; Turkey; Iran

Key companies profiled

Abbott (St. Jude Medical); Medtronic; Boston Scientific Corporation; Aleva Neurotherapeutics S.A.; Nexstim; LivaNova PLC; Neuropace Inc.

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2028. For the purpose of this study, Grand View Research has segmented the global Deep Brain Stimulation (DBS) devices market report on the basis of product, application, end-use, and region:

  • Product Outlook (Revenue, USD Million, 2016 - 2028)

    • Single Channel

    • Dual Channel

  • Application Outlook (Revenue, USD Million, 2016 - 2028)

    • Pain Management

    • Epilepsy

    • Essential Tremor

    • Obsessive Compulsive Disorder (OCD)

    • Depression

    • Dystonia

    • Parkinson’s Disease

    • Others

  • End-use Outlook (Revenue, USD Million, 2016 - 2028)

    • Hospitals

    • Neurology Clinics

    • Ambulatory Surgical Centers

    • Research Centers

  • Regional Outlook (Revenue, USD Million, 2016 - 2028)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Russia

      • Netherlands

      • Switzerland

      • Sweden

      • Ireland

      • Poland

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Indonesia

      • Thailand

      • Philippines

      • Malaysia

      • Singapore

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

      • Chile

      • Venezuela

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Turkey

      • Iran

Frequently Asked Questions About This Report

Pricing & Purchase Options

Service Guarantee

  • Insured Buying

    This report has a service guarantee. We stand by our report quality.

  • Confidentiality

    We are in compliance with GDPR & CCPA norms. All interactions are confidential.

  • GDPR.EU
  • Custom research service

    Design an exclusive study to serve your research needs.

  • 24/5 Research support

    Get your queries resolved from an industry expert.

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities